Overview

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The present study will assess the low-density lipoprotein cholesterol (LDL-C) lowering effect of colesevelam as an adjunct to niacin for the improvement of lipids and glycemic control in dyslipidemic subjects with impaired fasting glucose.
Phase:
Phase 4
Details
Lead Sponsor:
Radiant Research
Treatments:
Colesevelam Hydrochloride
Niacin
Niacinamide
Nicotinic Acids